Jane Street’s Quince Therapeutics QNCX Stock Holding History

Jane Street’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$230K	Buy	+12,642	New	+$291K	﹤0.01%	9795
2026 Q1	–	Sell	-2,605	Closed	-$1.75M	–	12723
2025 Q4	$1.75M	Buy	2,605 +2,429	+1,380%	+$1.22M	﹤0.01%	5061
2025 Q3	$57.3K	Buy	+176	New	+$58.6K	﹤0.01%	10313
2025 Q1	–	Sell	-52	Closed	-$19.6K	–	10394
2024 Q4	$19.6K	Buy	+52	New	+$15.6K	﹤0.01%	9132
2024 Q1	–	Sell	-599	Closed	-$126K	–	9914
2023 Q4	$126K	Buy	599 +220	+58%	+$44.1K	﹤0.01%	8481
2023 Q3	$85K	Buy	+379	New	+$99K	﹤0.01%	8014
2022 Q1	–	Sell	-269	Closed	-$366K	–	10895
2021 Q4	$677K	Buy	269 +153	+132%	+$934K	﹤0.01%	6700
2021 Q3	$2.13M	Buy	+116	New	+$1.84M	﹤0.01%	4348
2020 Q4	–	Sell	-66	Closed	-$661K	–	7992
2020 Q3	$661K	Buy	+66	New	+$600K	﹤0.01%	4744

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street's QNCX Position: Q2 2026 in Review

Jane Street opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 12,642 shares worth $230K. The stake represents ﹤0.01% of the portfolio and ranks #9795 among its holdings. This is a return to the name: Jane Street previously reported a position in QNCX as recently as Q4 2025.

Jane Street first reported a position in QNCX in Q3 2020 and has held it in 9 quarters since. The position peaked at $2.13M in Q3 2021. 25 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

Jane Street held 12,642 shares of Quince Therapeutics worth $230K as of Q2 2026.
Quince Therapeutics was a new Jane Street position in Q2 2026.
Quince Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #9795 holding.
Jane Street first reported a position in Quince Therapeutics in Q3 2020 and has held it in 9 quarters since.
Jane Street's Quince Therapeutics position peaked at $2.13M in Q3 2021.
25 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.